MediciNova Secures $30 Million Standby Equity Agreement to Advance Neurological and Fibrotic Disease Programs
核心洞察
MediciNova has signed a 36-month Standby Equity Purchase Agreement with Yorkville Advisors for up to $30 million to support R&D programs and general corporate activities.
The agreement provides flexible access to capital at 97% of market price without issuing warrants, allowing the company to take advantage of favorable market conditions.
Proceeds will advance development of MN-166 (ibudilast) for neurological disorders including ALS and progressive MS, and MN-001 (tipelukast) for fibrotic diseases like NAFLD.
MediciNova, Inc. has entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global LP (搜索) for up to $30 million worth of common stock over 36 months, providing the clinical-stage biopharmaceutical company with flexible financing to advance its neurological and fibrotic disease programs.
Financing Structure and Terms
Under the agreement announced July 31, 2025, MediciNova retains the right, but not the obligation, to sell common stock in individual transactions up to 100% of the daily volume traded during the five days immediately prior to each transaction date. The stock will be sold to investment funds managed by Yorkville Advisors, specifically YAII PN, Ltd (搜索), at a purchase price equal to 97% of the market price.
The arrangement allows MediciNova to access capital without issuing additional warrants, providing what CEO Dr. Yuichi Iwaki described as the ability "to take advantage of favorable market conditions." The SEPA structure offers flexible, non-obligatory access to equity financing without requiring immediate or full drawdown of the committed funds.
Strategic Pipeline Focus
MediciNova's development strategy centers on two lead compounds targeting serious diseases with unmet medical needs. The company is advancing MN-166 (ibudilast) for multiple neurological and other disorders, including amyotrophic lateral sclerosis (搜索) (ALS), progressive multiple sclerosis (搜索) (MS), chemotherapy-induced peripheral neuropathy (搜索), degenerative cervical myelopathy (搜索), glioblastoma (搜索), substance dependence (搜索) and addiction, prevention of acute respiratory distress syndrome (搜索) (ARDS), and Long COVID (搜索).
The second lead program involves MN-001 (tipelukast) for fibrotic and metabolic disorders such as nonalcoholic fatty liver disease (搜索) (NAFLD) and hypertriglyceridemia (搜索). The company plans to advance these programs through investigator-sponsored clinical trials, government-funded studies, internally funded trials, and strategic alliances.
Management Commentary and Market Position
Dr. Iwaki emphasized that the company's current financial position provides operational continuity while the SEPA offers additional strategic flexibility. "Our current cash position affords us the freedom to continue operations and amply fund our ongoing programs," he stated. "However, the SEPA provides us with additional flexibility to access capital to further support our R&D initiatives, expand our business, and pursue strategic opportunities."
The CEO noted that the agreement with YAII "validates our market position as well as our progress in our ongoing clinical activities." Proceeds from the equity transactions will be used to further advance R&D programs and support general corporate activities.
Company Profile and Market Focus
MediciNova operates as a clinical-stage biopharmaceutical company with a commercial focus on the United States market. The company trades on both the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), reflecting its international presence while maintaining its primary development focus on addressing unmet medical needs in serious diseases.